ACONMEDIUM SIGNALFINANCIAL10-K

ACON shows revenue growth but deepening losses as the medical technology company expanded its patent portfolio while extending patent expiration dates through 2037.

The company appears to be in an active development phase with growing R&D investments and patent acquisitions, but operating losses are widening despite revenue improvements. The significant increase in outstanding shares from 582,371 to 2,282,371 suggests substantial equity financing occurred during the period, likely to fund operations and development activities.

Comparing 2026-03-18 vs 2025-04-09View on EDGAR →
FINANCIAL ANALYSIS

ACON's financial profile reflects a development-stage medical technology company with revenue growing substantially while operating losses deepened from $5.5M to $7.1M. The company improved its balance sheet by reducing total liabilities by 27% to $837K and dramatically lowered interest expense from $608K to $64K, though operating cash flow remained negative at $7.2M. The nearly four-fold increase in outstanding shares indicates significant equity financing to support the business through its development phase.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-89.5%
$608K→$64K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Revenue
P&L
+65.6%
$46K→$76K

Strong top-line growth of 65.6% — accelerating demand or successful expansion into new markets.

Accounts Receivable
Balance Sheet
+62%
$18K→$30K

Receivables surged 62% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Operating Cash Flow
Cash Flow
-35.9%
-$5.3M→-$7.2M

Operating cash flow fell 35.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Operating Income
P&L
-27.9%
-$5.5M→-$7.1M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Total Liabilities
Balance Sheet
-27.4%
$1.2M→$837K

Liabilities reduced 27.4% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-27.4%
$1.2M→$837K

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
+16.3%
$889K→$1.0M

R&D investment increased 16.3% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-03-18
PRIOR — 2025-04-09
ADDED
As of March 17, 2026, 2,282,371 shares of the registrant s common stock, $0.00001 par value per share, were outstanding.
" Covered Entity is a health care provider or other person or entity who acquires and transmits private health information of patients, as covered under HIPAA and GDPR regulations (see e.g., 45 CFR 160.103).
As of December 31, 2025, our patent portfolio includes 28 U.S.
NMR equipment was used to conduct MRS chemical analysis of painful discs that were surgically removed for DLBP fusion surgery versus normal, non-painful discs that were surgically removed from spinal deformity (i.e., scoliosis) patients for lumbar spine reconstruction.
The patents subject to the License Agreement expire between 2026 and 2037, without considering any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees.
While MRS has been used previously for diagnosing certain cancers (e.g., brain, breast, prostate) by measuring unique chemical biomarkers for tumors, NOCISCAN uses MRS for measuring the relative levels of degenerative pain and structural integrity biomarkers in discs.
Aclarion enables MR imaging centers to transfer imaging data through a licensed, proprietary data transfer platform provided by Intelerad s AMBRA Healthcare.
Prior applications of MRS, e.g., for brain, prostate, or breast cancer diagnosis encountered technical challenges related to acquiring reliably robust spectra for making accurate quantitative chemical measurements.
Without strong clinical data supporting our technology s ability to improve clinical outcomes, the opportunity to secure new reimbursement codes and change existing treatment pathways would be limited.
Clinical improvement post-surgically was evaluated using the industry standard Oswestry Disability Index (ODI), and the Visual Analog Scale (VAS).
REMOVED
As of April 9, 2025, 582,371 shares of the registrant s common stock, $0.00001 par value per share, were outstanding.
" Covered Entity is a health care provider or other person or entity who acquires and transmits private health information of patients, as covered under HIPAA and GDPR regulations (see e.g.
We have entered into joint ventures with certain hospitals both provide and manage their diagnostic imaging services, allowing them to leverage our industry expertise.
NMR equipment was used to conduct MRS chemical analysis of painful discs that were surgically removed for DLBP fusion surgery versus normal, non-painful discs that were surgically removed from spinal deformity (i.e.
The patents subject to the License Agreement expire between 2025 and 2029.
(not adjusted for subsequent stock splits) In 2015, NuVasive, Inc.
( NuVasive ) purchased approximately $2.0 million of the Company s Series B preferred shares.
NuVasive and the Company also entered into a marketing agreement pursuant to which NuVasive would be the exclusive, other than the Company, marketing provider for the Company s technology and NuVasive would receive a commission (the Commission ) of all sales of the technology made by NuVasive.
The ROFO obligations will expire 42 months after the FDA issues its first regulatory clearance of a Company product or service.
The ROFO obligations do not apply to any proposed sale event in which the acquisition price is $40 million or more.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →